| (Values in U.S. Thousands) | Jun, 2022 | Jun, 2021 | Jun, 2020 | Jun, 2019 | Jun, 2018 |
| Sales | 330 | 500 | 2,450 | 41,690 | 24,190 |
| Sales Growth | -34.00% | -79.59% | -94.12% | +72.34% | -38.71% |
| Net Income | -68,940 | -57,830 | -45,890 | -2,010 | -21,300 |
| Net Income Growth | -19.21% | -26.02% | -2,183.09% | +90.56% | -5,295.12% |
Applied Genetic Tech (AGTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.
Fiscal Year End Date: 06/30